Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 9/2019

Open Access 01-09-2019 | Breast Cancer | Breast Oncology

Clinicopathological Features and Disease Outcome in Breast Cancer Patients with Hormonal Receptor Discordance between Core Needle Biopsy and Following Surgical Sample

Authors: Siji Zhu, MD, PhD, Jiayi Wu, MD, PhD, Ou Huang, MD, PhD, Jianrong He, MD, PhD, Li Zhu, MD, PhD, Yafen Li, MD, Weiguo Chen, MD, Xiaochun Fei, MD, PhD, Xiaosong Chen, MD, PhD, Kunwei Shen, MD, PhD

Published in: Annals of Surgical Oncology | Issue 9/2019

Login to get access

Abstract

Background

There are limited data about how to manage patients with discordant hormonal receptor (HR) status between core needle biopsy (CNB) and following surgical sample (FSS). This study aimed to evaluate clinicopathological features and disease outcome for these HR discordance patients.

Patients and Methods

Invasive breast cancer patients with paired HR between CNB and FSS were retrospectively analyzed, being classified into three groups: HR positive, HR negative, and HR discordance. Patient characteristics, treatment decisions, and disease outcome were compared among above groups.

Results

A total of 1710 patients (1233 HR positive, 417 HR negative, and 60 HR discordance patients) were enrolled. Compared with the HR positive group, HR discordance patients were associated with more human epidermal growth factor receptor 2 positivity (P < 0.001) and higher Ki67 level (P = 0.001) tumors. The fraction of patients receiving adjuvant chemotherapy was 95.0% and 93.8% in the HR discordance or HR negative groups, much higher than in the HR positive group (66.7%, P < 0.001). Of 60 HR discordance patients, 34 (56.7%) received adjuvant endocrine therapy. The 5-year disease-free survival (DFS) rate was 90.4% for HR discordant patients, showing no statistical difference compared with HR positive (87.0%, P = 0.653) or HR negative (83.2%, P = 0.522) groups. For HR discordance patients, there was no difference in DFS between patients who received adjuvant endocrine therapy or not (P = 0.259).

Conclusions

HR discordance patients had similar tumor characteristics, adjuvant chemotherapy treatment, and DFS compared with HR negative patients. The benefit of endocrine therapy in these HR discordance patients is uncertain and deserves further clinical evaluation.
Appendix
Available only for authorised users
Literature
1.
Verkooijen HM, Peeters PH, Buskens E, et al. Diagnostic accuracy of large-core needle biopsy for nonpalpable breast disease: a meta-analysis. Br J Cancer. 2000; 82: 1017–21.CrossRefPubMedPubMedCentral
2.
Dillon MF, Hill AD, Quinn CM, et al. The accuracy of ultrasound, stereotactic, and clinical core biopsies in the diagnosis of breast cancer, with an analysis of false- negative cases. Ann Surg. 2005; 242: 701–7.CrossRefPubMedPubMedCentral
3.
Bruening W, Fontanarosa J, Tipton K, et al. Systematic review: comparative effectiveness of core-needle and open surgical biopsy to diagnose breast lesions. Ann Intern Med. 2010; 152(4):238–46.CrossRefPubMed
4.
Cahill RA, Walsh D, Landers RJ, et al. Preoperative profiling of symptomatic breast cancer by diagnostic core biopsy. Ann Surg Oncol. 2006; 13(1):45–51.CrossRefPubMed
5.
Lorgis V, Algros MP, Villanueva C, et al. Discordance in early breast cancer for tumour grade, estrogen receptor, progesteron receptors and human epidermal receptor-2 status between core needle biopsy and surgical excisional primary tumour. Breast. 2011; 20(3):284–7.CrossRefPubMed
6.
Arnedos M, Nerurkar A, Osin P, et al. Discordance between core needle biopsy (CNB) and excisional biopsy (EB) for estrogen receptor (ER), progesterone receptor (PgR) and HER2 status in early breast cancer (EBC). Ann Oncol. 2009; 20(12):1948–52.CrossRefPubMed
7.
Chen X, Sun L, Mao Y, et al. Preoperative core needle biopsy is accurate in determining molecular subtypes in invasive breast cancer. BMC Cancer. 2013; 13:390–6.CrossRefPubMedPubMedCentral
8.
Senkus E, Kyriakides S, Ohno S, et al. Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015; 26(Suppl 5):v8–30.CrossRefPubMed
9.
Hammond ME, Hayes DF, Dowsett M, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol. 2010; 28(16):2784–95.CrossRefPubMedPubMedCentral
10.
1Wolff AC, Hammond ME, Hicks DG, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol. 2013; 31(31):3997–4013.CrossRefPubMed
11.
1Perou CM, T Sorlie, MB Eisen, et al. Molecular portraits of human breast tumours. Nature. 2000; 406:747–52.CrossRefPubMed
12.
1Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 2001; 98(19):10869–74.CrossRefPubMed
13.
1Coates AS, Winer EP, Goldhirsch A, et al. Tailoring therapies–improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. Ann Oncol. 2015; 26(8):1533–46.CrossRefPubMedPubMedCentral
14.
1Fan L, Strasser-Weippl K, Li JJ, et al. Breast cancer in China. Lancet Oncol. 2014, 15(7): e279–89.CrossRefPubMed
15.
1Chen X, Yuan Y, Shen K, et al. Accuracy of estrogen receptor, progesterone receptor, and HER2 status between core needle and open excision biopsy in breast cancer: a meta-analysis. Breast Cancer Res Treat. 2012; 134(3):957–67.CrossRefPubMed
16.
1Mann GB, Fahey VD, Feleppa F, et al. Reliance on hormone receptor assays of surgical specimens may compromise outcome in patients with breast cancer. J Clin Oncol. 2005; 23(22):5148–54.CrossRefPubMed
17.
1Uy GB, Laudico AV, Carnate JM Jr, et al. Breast cancer hormone receptor assay results of core needle biopsy and modified radical mastectomy specimens from the same patients. Clin Breast Cancer. 2010; 10(2):154–9.CrossRefPubMedPubMedCentral
18.
1Zidan A, Christie Brown JS, et al. Oestrogen and progesterone receptor assessment in core biopsy specimens of breast carcinoma. J Clin Pathol. 1997; 50(1):27–9.CrossRefPubMedPubMedCentral
19.
1Fujii T, Kogawa T, Dong W, et al. Revisiting the definition of estrogen receptor positivity in HER2-negative primary breast cancer. Ann Oncol. 2017; 28(10):2420–8.CrossRefPubMedPubMedCentral
20.
Goldhirsch A, Ingle JN, Gelber RD, et al. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol. 2009; 20(8):1319–29.CrossRefPubMedPubMedCentral
21.
de Azambuja E, Cardoso F, de Castro G, et al Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients. Br J Cancer. 2007; 96(10):1504–13.CrossRefPubMedPubMedCentral
22.
Dowsett M, Nielsen TO, A’Hern R, et al. Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. J Natl Cancer Inst. 2011; 103(22):1656–64.CrossRefPubMedPubMedCentral
Metadata
Title
Clinicopathological Features and Disease Outcome in Breast Cancer Patients with Hormonal Receptor Discordance between Core Needle Biopsy and Following Surgical Sample
Authors
Siji Zhu, MD, PhD
Jiayi Wu, MD, PhD
Ou Huang, MD, PhD
Jianrong He, MD, PhD
Li Zhu, MD, PhD
Yafen Li, MD
Weiguo Chen, MD
Xiaochun Fei, MD, PhD
Xiaosong Chen, MD, PhD
Kunwei Shen, MD, PhD
Publication date
01-09-2019
Publisher
Springer International Publishing
Published in
Annals of Surgical Oncology / Issue 9/2019
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-019-07480-y

Other articles of this Issue 9/2019

Annals of Surgical Oncology 9/2019 Go to the issue

Endocrine Tumors

Outcomes of Lymph Node Dissection for Non-metastatic Pancreatic Neuroendocrine Tumors: A Propensity Score-Weighted Analysis of the National Cancer Database

Breast Oncology

Editorial on “Neoadjuvant Chemotherapy Does Not Increase Complications in Oncoplastic Breast-Conserving Surgery”

Breast Oncology

Clinical Validation of the BREAST-Q Breast-Conserving Therapy Module

Gastrointestinal Oncology

Prophylactic Cervical Lymph Node Dissection in Thoracoscopic Esophagectomy for Esophageal Cancer Increases Postoperative Complications and Does Not Improve Survival

Gastrointestinal Oncology

Natural History of Gastric Cancer: Observational Study of Gastric Cancer Patients Not Treated During Follow-Up

Melanoma

Utility of Level III Axillary Node Dissection in Melanoma Patients with Palpable Axillary Lymph Node Disease